Immunic (IMUX) appointed Elena Ridloff, CFA, to its Board of Directors, effective August 6, 2026. The company said Ridloff brings more than 20 years of experience in finance, corporate development, investor relations and capital markets across the biopharmaceutical industry.
Ridloff currently serves as Chief Financial Officer at Sionna Therapeutics. Immunic said the appointment comes as it approaches top-line data from its Phase 3 ENSURE trials of vidofludimus calcium in relapsing multiple sclerosis, expected by year-end, and a planned Phase 3 program in progressive multiple sclerosis.
- Board appointment: Elena Ridloff joined Immunic’s Board of Directors effective August 6, 2026.
- Current role: Ridloff is Chief Financial Officer at Sionna Therapeutics.
- Prior experience: She previously served as Executive Vice President and Chief Financial Officer of ACADIA Pharmaceuticals.
- Capital markets background: Immunic said Ridloff played a key role in raising $600 million in capital at ACADIA Pharmaceuticals.
- Clinical milestone: Top-line data from the Phase 3 ENSURE trials in relapsing multiple sclerosis are expected by the end of 2026.
- Pipeline plan: Immunic expects to initiate an additional Phase 3 clinical trial in progressive multiple sclerosis later in 2026.
$IMUX Hedge Fund Activity
We have seen 51 institutional investors add shares of $IMUX stock to their portfolio, and 32 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BVF INC/IL added 6,887,675 shares (+900.0%) to their portfolio in Q1 2026, for an estimated $76,453,192
- LAURION CAPITAL MANAGEMENT LP added 3,493,946 shares (+900.0%) to their portfolio in Q1 2026, for an estimated $38,782,800
- 683 CAPITAL MANAGEMENT, LLC added 2,450,000 shares (+inf%) to their portfolio in Q1 2026, for an estimated $27,195,000
- MARSHALL WACE, LLP added 850,967 shares (+834.3%) to their portfolio in Q1 2026, for an estimated $9,445,733
- JANE STREET GROUP, LLC added 630,486 shares (+2199.3%) to their portfolio in Q1 2026, for an estimated $6,998,394
- IKARIAN CAPITAL, LLC added 607,196 shares (+900.0%) to their portfolio in Q1 2026, for an estimated $6,739,875
- UBS GROUP AG removed 484,838 shares (-90.3%) from their portfolio in Q1 2026, for an estimated $5,381,701
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
